Drug Trial Radar · NCT05113095
A Survey of Darvadstrocel in People With Crohn's Disease
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
275
Planned (sponsor's estimate)
Start
Nov 30, 2021
Primary completion
Dec 31, 2029
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Nov 9, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a survey in Japan of Darvadstrocel injection used to treat Crohn's disease people with complicated anal fistula. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from Darvadstrocel injection and to check if Darvadstrocel injection improves symptoms of Crohn's disease. During the study, participants with Crohn's disease will take Darvadstrocel injection according to their clinic's standard practice. The study doctors will check for side effects from Darvadstrocel for 36 months.
Conditions
- Crohn's Disease
Interventions
DarvadstrocelBiological
Darvadstrocel injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse EventsTime frame: 36 Months
- Percentage of Participants who Achieve Clinical ResponseTime frame: Baseline, Up to Months 36
- Percentage of Participants who Achieve Clinical RemissionTime frame: Baseline, Up to Months 36
- Percentage of Participants who Achieve Combined RemissionTime frame: Baseline, Up to Months 36
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Takeda Selected Site
Tokyo, Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.